These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 8598468)

  • 1. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
    Irvine KR; Rao JB; Rosenberg SA; Restifo NP
    J Immunol; 1996 Jan; 156(1):238-45. PubMed ID: 8598468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
    Specht JM; Wang G; Do MT; Lam JS; Royal RE; Reeves ME; Rosenberg SA; Hwu P
    J Exp Med; 1997 Oct; 186(8):1213-21. PubMed ID: 9334360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
    Chen PW; Wang M; Bronte V; Zhai Y; Rosenberg SA; Restifo NP
    J Immunol; 1996 Jan; 156(1):224-31. PubMed ID: 8598466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
    Rao JB; Chamberlain RS; Bronte V; Carroll MW; Irvine KR; Moss B; Rosenberg SA; Restifo NP
    J Immunol; 1996 May; 156(9):3357-65. PubMed ID: 8617961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
    Carroll MW; Overwijk WW; Chamberlain RS; Rosenberg SA; Moss B; Restifo NP
    Vaccine; 1997 Mar; 15(4):387-94. PubMed ID: 9141209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
    Bronte V; Tsung K; Rao JB; Chen PW; Wang M; Rosenberg SA; Restifo NP
    J Immunol; 1995 May; 154(10):5282-92. PubMed ID: 7730632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.
    Gurunathan S; Irvine KR; Wu CY; Cohen JI; Thomas E; Prussin C; Restifo NP; Seder RA
    J Immunol; 1998 Nov; 161(9):4563-71. PubMed ID: 9794383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.
    Wang M; Chen PW; Bronte V; Rosenberg SA; Restifo NP
    J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):139-46. PubMed ID: 8770769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
    Rodolfo M; Salvi C; Bassi C; Parmiani G
    Cancer Immunol Immunother; 1990; 31(1):28-36. PubMed ID: 2306753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
    Wang M; Bronte V; Chen PW; Gritz L; Panicali D; Rosenberg SA; Restifo NP
    J Immunol; 1995 May; 154(9):4685-92. PubMed ID: 7722321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope.
    Ryan MH; Bristol JA; McDuffie E; Abrams SI
    J Immunol; 2001 Oct; 167(8):4286-92. PubMed ID: 11591751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-induced activation of adaptive and innate antitumor immunity.
    van den Broeke LT; Daschbach E; Thomas EK; Andringa G; Berzofsky JA
    J Immunol; 2003 Dec; 171(11):5842-52. PubMed ID: 14634094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
    Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
    Ann Ist Super Sanita; 1990; 26(3-4):423-32. PubMed ID: 2091504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus.
    Takeda J; Sato Y; Kiyosawa H; Mori T; Yokoya S; Irisawa A; Miyata M; Obara K; Fujita T; Suzuki T; Kasukawa R; Wanaka A
    Cell Immunol; 2000 Aug; 204(1):11-8. PubMed ID: 11006013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA.
    Kawano H; Nishikawa M; Mitsui M; Takahashi Y; Kako K; Yamaoka K; Watanabe Y; Takakura Y
    Int J Cancer; 2007 Jul; 121(2):401-6. PubMed ID: 17372909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma.
    Ruehlmann JM; Xiang R; Niethammer AG; Ba Y; Pertl U; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Dec; 61(23):8498-503. PubMed ID: 11731434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization.
    Raz E; Tighe H; Sato Y; Corr M; Dudler JA; Roman M; Swain SL; Spiegelberg HL; Carson DA
    Proc Natl Acad Sci U S A; 1996 May; 93(10):5141-5. PubMed ID: 8643542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis.
    Rodrigo-Garzón M; Berraondo P; Ochoa L; Zulueta JJ; González-Aseguinolaza G
    Cancer Gene Ther; 2010 Jan; 17(1):20-7. PubMed ID: 19575045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.